Novartis Investigative Site

Florianópolis, Santa Catarina 88040-970

0 studies enrolling now · 10 studies all time

What they study most

Asthma, Breast Cancer, Gastrointestinal Stromal Tumor (GIST), Leukemia, Myelomonocytic, Chronic, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndromes, Neoplasms, Gastrointestinal Tract, Non-small Cell Lung Cancer, Thrombocytopaenia

Studies at this site

• Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. — Running, not enrolling
• Roll-over Study to Allow Continued Access to Ribociclib — Running, not enrolling
• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) — Stopped early
• Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer — Completed
• LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib — Completed
• Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. — Completed
• A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) — Stopped early
• A Study of Nilotinib Versus Imatinib in GIST Patients — Completed
• Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma — Completed
• Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer — Completed